NUCALA HAS AN ESTABLISHED SAFETY PROFILE

In a 52-week clinical trial in patients with CRSwNP (N=407):

ADVERSE REACTIONS WITH NUCALA WITH ≥3% INCIDENCE AND MORE COMMON THAN PLACEBO IN PATIENTS WITH CRSwNP

Adverse Reaction NUCALA %
(n=206)
Placebo %
(n=201)
Oropharyngeal pain 8 5
Arthralgia 6 2
Abdominal pain upper 3 2
Diarrhea 3 2
Pyrexia 3 2
Nasal dryness 3 <1
Rash 3 <1
  • Systemic reactions, including hypersensitivity: <1% NUCALA, <1% placebo
    • Manifestations included urticaria, erythema, and rash. 1 of 3 reactions occurred on the day of dosing
  • Injection site reactions (eg, erythema, pruritus): 2% NUCALA, <1% placebo 

  • Immunogenicity: In patients receiving NUCALA, 3% (n=6) developed anti-mepolizumab antibodies and none had neutralizing antibodies detected. The clinical relevance of anti-mepolizumab antibodies is not known 

  • There were no serious adverse events of herpes zoster in patients receiving NUCALA

Navigate a NUCALA prescription

Start with MyNUCALA

Live Agent Available now
NUCALA Virtual Assistant

XXX

INDICATIONS & IMPORTANT SAFETY INFO
INDICATIONS

NUCALA is indicated for the:

  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids.

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients. 

NUCALA is indicated for the: 

  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids. 
IMPORTANT SAFETY INFORMATION

NUCALA is indicated for the:

  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids.

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.